10 drug(s) with this reaction
8,642 total reports
Constipation has been reported as an adverse reaction across 10 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 8,642 adverse event reports mention constipation in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with constipation, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have constipation listed in their FDA adverse event reports, sorted by report count:
In addition to constipation, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
10 drug(s) manufactured by Amgen Inc have constipation listed in their FDA adverse event reports: ERENUMAB-AOOE, DENOSUMAB, PEGFILGRASTIM, DARBEPOETIN ALFA, FILGRASTIM, and others.
There are a combined 8,642 reports of constipation across 10 Amgen Inc drug(s) in the FDA adverse event database.